BCM
NVS icon

Brooktree Capital Management’s Novartis NVS Stock Holding History

Brooktree Capital Management’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,542
Closed -$232K – 43
2021
Q2 		$232K Hold
2,542
– – 0.15% 40
2021
Q1 		$217K Sell
2,542
-5,327
-68% -$478K 0.15% 42
2020
Q4 		$743K Sell
7,869
-420
-5% -$36.7K 0.55% 34
2020
Q3 		$720K Sell
8,289
-50
-0.6% -$4.33K 0.61% 33
2020
Q2 		$728K Sell
8,339
-1,190
-12% -$103K 0.68% 32
2020
Q1 		$786K Sell
9,529
-185
-2% -$16.5K 0.91% 27
2019
Q4 		$920K Buy
+9,714
New +$872K 0.84% 31

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aristotle Capital Management
Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Brooktree Capital Management's NVS Position: Q3 2021 in Review

Brooktree Capital Management sold out of Novartis (NVS) in Q3 2021, closing a stake of 2,542 shares — an estimated $232K sold.

Brooktree Capital Management first reported a position in NVS in Q4 2019 and held it in 7 quarters. The position peaked at $920K in Q4 2019. 1,080 funds tracked by Wall St. Rank hold NVS as of Q3 2021.

  • Brooktree Capital Management reported no remaining Novartis position as of Q3 2021 after selling out during the quarter.
  • Brooktree Capital Management sold 2,542 Novartis shares in Q3 2021, an estimated $232K.
  • Brooktree Capital Management first reported a position in Novartis in Q4 2019 and held it in 7 quarters.
  • Brooktree Capital Management's Novartis position peaked at $920K in Q4 2019.
  • 1,080 funds tracked by Wall St. Rank held Novartis as of Q3 2021.

Based on Brooktree Capital Management's 13F filing for Q3 2021, filed 9 Nov 2021.